全文获取类型
收费全文 | 2816篇 |
免费 | 344篇 |
国内免费 | 66篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 60篇 |
妇产科学 | 48篇 |
基础医学 | 93篇 |
口腔科学 | 9篇 |
临床医学 | 357篇 |
内科学 | 785篇 |
皮肤病学 | 17篇 |
神经病学 | 97篇 |
特种医学 | 31篇 |
外国民族医学 | 5篇 |
外科学 | 147篇 |
综合类 | 326篇 |
预防医学 | 79篇 |
眼科学 | 17篇 |
药学 | 582篇 |
2篇 | |
中国医学 | 128篇 |
肿瘤学 | 440篇 |
出版年
2024年 | 6篇 |
2023年 | 76篇 |
2022年 | 105篇 |
2021年 | 157篇 |
2020年 | 156篇 |
2019年 | 137篇 |
2018年 | 174篇 |
2017年 | 160篇 |
2016年 | 135篇 |
2015年 | 121篇 |
2014年 | 198篇 |
2013年 | 285篇 |
2012年 | 173篇 |
2011年 | 161篇 |
2010年 | 151篇 |
2009年 | 113篇 |
2008年 | 107篇 |
2007年 | 113篇 |
2006年 | 85篇 |
2005年 | 93篇 |
2004年 | 65篇 |
2003年 | 46篇 |
2002年 | 50篇 |
2001年 | 48篇 |
2000年 | 41篇 |
1999年 | 33篇 |
1998年 | 32篇 |
1997年 | 13篇 |
1996年 | 17篇 |
1995年 | 16篇 |
1994年 | 18篇 |
1993年 | 18篇 |
1992年 | 17篇 |
1991年 | 13篇 |
1990年 | 10篇 |
1989年 | 11篇 |
1988年 | 11篇 |
1987年 | 9篇 |
1986年 | 9篇 |
1985年 | 6篇 |
1984年 | 8篇 |
1983年 | 4篇 |
1982年 | 7篇 |
1981年 | 5篇 |
1980年 | 5篇 |
1979年 | 3篇 |
1978年 | 1篇 |
1977年 | 3篇 |
1974年 | 1篇 |
排序方式: 共有3226条查询结果,搜索用时 19 毫秒
1.
《Cancer radiothérapie》2022,26(4):611-615
In order to provide more convenient irradiation regimens for patient comfort, radiation facility organization and health expenses, new hypofractionated protocols have been evaluated. Moderately (dose/fraction: 2.3 to 3 Gy), then ultra (dose/fraction: 5.2 to 6.1 Gy) hypofractionated irradiations were first validated. The current question is: is it possible to go forward using extreme hypofractionated regimens (EHR) based on 1 to 3 fractions. Different irradiation techniques are under investigation. However, brachytherapy remains the smartest way to deliver a high dose in a small volume. We report prospective and retrospective study results which evaluated EHR for breast and prostate brachytherapy. While oncological outcome and toxicity profile appear extremely encouraging for low-risk breast cancer after a 1 to 4 fractions (6.25 to 20 Gy/fraction), the use of a single fraction of 19 to 23 Gy appears debatable for prostate cancer. Brachytherapy represents an emblematic example of EHR but longer follow-up and more mature results are awaited in order to specify the right indications and refine the EQD2 calculation method including new biological and technical factors. 相似文献
2.
《Saudi Pharmaceutical Journal》2022,30(6):849-855
The emergence of carbapenem-resistant organisms posed considerable threat to global health while only limited treatment options are available and led to efforts to discover a novel way to treat them. To evaluate in vitro synergistic activity of meropenem plus ertapenem, a total of 203 carbapenem-resistant strains, collected from 12 provinces and municipalities in China, were examined with a dual carbapenem combination therapy. The statistical software R was used for analysis. Two hundred and one (201) of carbapenem-resistant strains mainly produced four types of carbapenemase: KPC-2 (n = 142, 69.95%), OXA-232 (n = 7, 3.45%), NDM (n = 38, 18.72%; 36 NDM-1, 1 NDM-4, 1 NDM-5), and IMP (n = 15, 7.39%; 1 IMP-26, 10 IMP-30, 4 IMP-4). Fifty-one out of two hundred and three (51/203 or 25.12%) of the examined strains showed a synergistic effect for the meropenem plus ertapenem combination throughout the checkerboard method, while only three isolates showed potential clinically relevant synergy (3/203, 1.48%). An additive effect was observed in 55/203 (27.09%) of the examined strains. Ninety-seven of the examined isolates (47.78%) showed fractional inhibitory concentration (FIC) greater or equal to 2 (indicating antagonism). The synergistic activity of meropenem plus ertapenem combination suggests this combination can be a possible way to treat the infection caused by the carbapenem-resistant organisms, especially for IMP or NDM producer with a lesser minimum inhibitory concentration (MIC) and the infected individual who was not recommended to use colistin or tigecycline. 相似文献
3.
Adjuvant irradiation is the standard treatment after breast conservative surgery. Normofractionated regimen with an overall treatment time of 5 to 6 weeks is often considered as a limiting factor for irradiation compliance. In order to answer this issue, moderate and more recently extreme hypofractionated protocols appeared. We report here oncological outcomes and toxicity of hypofractionated breast irradiation. After defining the frame of moderate and extreme hypofractionated breast irradiations based on overall treatment time, patient selection criteria were listed. According to their levels of proof, the results of moderate and extreme hypofractionated breast irradiation were analysed. Overall treatment time for moderate hypofractionated breast irradiation ranged from 3 to 4 weeks, while for extreme hypofractionated breast irradiation, it was less than 1 week. For moderate hypofractionated breast irradiation, whole breast irradiation was currently performed with or without lymph node irradiation. Moderate hypofractionated breast irradiation has proven to be as safe and as efficient as normofractionated breast irradiation with level IA evidence. For extreme hypofractionated breast irradiation, phase III randomized trials confirmed that accelerated partial breast irradiation was non-inferior in terms of local control compared to normofractionated whole breast irradiation (with external beam radiation therapy and multicatheter brachytherapy), with similar acute and late toxicity. While the use of intraoperative breast irradiation remains under debate, new very accelerated partial breast irradiation (overall treatment time not exceeding 2 days) protocols emerged with encouraging results. Accelerated partial breast irradiation is warranted for extreme hypofractionated breast irradiation and is indicated for low-risk breast cancers. Moderate and extreme hypofractionated breast irradiation regimens are validated and can be routinely proposed according to patient selection criteria. 相似文献
4.
《Archives of Cardiovascular Diseases》2022,115(10):505-513
Central illustration: cumulative major adverse cardiac events (MACE) and bioresorbable vascular scaffold (BVS) thrombosis rates after 1, 2, 3, 4 and 5 years. 相似文献
5.
目的 研究缺血性脑血管病患者脑微出血(CMB)危险因素及其对抗血小板单药治疗的影响。方法 选取2018年1月至2018年6月该院神经内科接受抗血小板单药治疗的急性缺血性脑血管病患者300例为样本,入院后采集基本资料并完善相关检查,根据梯度回波T2*加权成像(GRE-T2*WI)检查结果将患者分为CMB组(176例)和非CMB组(124例),均给予抗血小板聚集治疗,比较两组临床资料及治疗1年内再发梗死、脑出血和病死率,分析影响CMB发病的危险因素以及CMB对抗血小板单药治疗的影响。结果 高龄、高血压、肥胖、脑卒中病史、ACI和脑白质疏松为CMB发生的危险因素(P<0.05)。CMB组和非CMB组抗血小板单药治疗期间脑出血率分别为14.20%和6.45%,差异有统计学意义(P<0.05)。轻度组、中度组和重度组脑出血率分别为9.18%、10.64%和35.48%,差异有统计学意义(P<0.05)。不同部位CMB患者抗血小板单药治疗期间再发脑梗死、脑出血及病死率比较,差异无统计学意义(P>0.05)。结论 高龄、高血压、肥胖、脑卒中病史、ACI及脑白质疏松为缺血性脑血管疾病合并CMB的危险因素。CMB可导致抗血小板单药治疗期间脑出血风险增加,重度CMB者更甚。 相似文献
6.
7.
目的 探讨儿童双相情感障碍经不同药物方案治疗后代谢指标的变化及治疗疗效。方法 回顾性分析2017年1月至2020年1月于该院就诊的220例儿童双相情感障碍患儿的临床资料。根据治疗方法分组,单纯采用非典型抗精神病药物治疗的112例患儿纳入对照组,采用非典型抗精神病药物联合心境稳定剂治疗的108例患儿纳入研究组。比较两组基线资料水平,治疗前后代谢指标空腹胰岛素(FIN)、糖化血红蛋白(HbAlc)、总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)水平变化,以及代谢综合征发生情况及临床疗效。结果 两组患儿年龄、性别、病程等基线资料比较差异均无统计学意义(P > 0.05)。研究组总有效率为92.6%,高于对照组(82.1%,P < 0.05)。治疗前,两组FIN、HbAlc水平比较差异无统计学意义(P > 0.05);治疗后,对照组FIN水平高于治疗前,且高于研究组(P < 0.05);但研究组治疗前后FIN水平比较差异无统计学意义(P > 0.05);两组治疗前后HbAlc水平比较差异无统计学意义(P > 0.05)。治疗前,两组TC、TG、HDL-C、LDL-C水平比较,差异无统计学意义(P > 0.05);治疗后,对照组TC、TG水平均高于治疗前,且高于研究组(P < 0.05);但研究组治疗前后TC、TG水平比较差异无统计学意义(P > 0.05);两组治疗前后HDL-C、LDL-C水平比较差异无统计学意义(P > 0.05)。研究组代谢综合征发生率(2.8%)低于对照组(9.8%)(P < 0.05)。结论 儿童双相情感障碍采用非经典抗精神病药物联合心境稳定剂治疗对代谢指标水平影响较小,且疗效显著。 相似文献
8.
Sameer Arora Kamal Shemisa Muthiah Vaduganathan Arman Qamar Ankur Gupta Sushil K. Garg Dharam J. Kumbhani Helen Mayo Houman Khalili Ambarish Pandey Sandeep R. Das 《Journal of the American College of Cardiology》2019,73(19):2454-2464
Ticagrelor is a cornerstone of modern antithrombotic therapy alongside aspirin in patients with acute coronary syndrome and after percutaneous coronary intervention. Adverse effects such as bleeding and dyspnea have been associated with premature ticagrelor discontinuation, which may limit any potential advantage of ticagrelor over clopidogrel. The randomized trials of ticagrelor captured adverse events, offering the opportunity to more precisely quantify these effects across studies. Therefore, a meta-analysis of 4 randomized clinical trials of ticagrelor conducted between January 2007 and June 2017 was performed to quantify the incidence and causes of premature ticagrelor discontinuation. Among 66,870 patients followed for a median 18 months, premature ticagrelor discontinuation was seen in 25%; bleeding was the most common cause of discontinuation followed by dyspnea. Versus the comparators, the relative risk of dyspnea-related discontinuation during follow-up was 6.4-fold higher, the relative risk of bleeding was 3.2-fold higher, and the relative risk of discontinuation due to any adverse event was 59% higher for patients receiving ticagrelor. Understanding these potential barriers to adherence to ticagrelor is crucial for informed patient-physician decision making and can inform future efforts to improve ticagrelor adherence. This review discusses the incidence, causes, and biological mechanisms of ticagrelor-related adverse effects and offers strategies to improve adherence to ticagrelor. 相似文献
9.
用小鼠败血症系统感染模型,以感染小鼠肾匀浆活菌计数为标准,以庆大霉素为对照药,探讨日剂量单次与分两次给药两种方案对新氨基糖苷类抗生素89—07体内抗留作用的影响。结果表明大肠杆菌90-020、绿脓假单胞菌3—374、金葡球菌90—506对抗生素89—07和庆大霉素均敏感(MIC范围0.0625~2mg/L);抗生素89—07和庆大霉素日剂量单次给药组(OD)3株实验菌的肾匀浆活菌计数值由给药前的4.94±0.09、4.60±0.27、4.86±0.101gcfu/ml分别降至1.94±0.19、1.84±0.25、1.88±0.251gcfu/ml(给药后7~8h).日剂量分两次给药组(BID)则分别降至2.95±0.48、2.87±0.37、3.44±0.271gcfu/ml。OD组对3株实验菌的最大杀菌作用Emax分别为3.02、2.97和2.851gcfu/ml,OD给药方案的体内杀菌作用明显优于BID方案。 相似文献
10.
Cancer chemotherapy with the application of several drugs is studied. The negative and inhibiting effect of the tumour on normal cells is taken into account. Under certain hypotheses, we determine the optimal regimen that minimizes the tumour burden at the end of a fixed period of therapy while maintaining several normal cell populations above prescribed levels. More precisely, it is demonstrated that the optimal drug administration corresponds to the strategy of intensive chemotherapy. 相似文献